Cancer and nausea

Chemotherapy Induced Nausea & Vomiting: Global Clinical Trials Review H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 3, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Medicine, Health, Clinical medicine, Oncology, Antineoplastic drugs, Chemotherapy-induced nausea and vomiting, Clinical trial, Chemotherapy, Electroacupuncture, Cancer and nausea

The "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario.
  • The report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Chemotherapy Induced Nausea & Vomiting - 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 20, 2020
Health, Pharmaceutical, Medicine, Clinical medicine, Health, Oncology, Antineoplastic drugs, Antiemetics, 5-HT3 antagonists, Chemotherapy-induced nausea and vomiting, Chemotherapy, Nausea, Vomiting, Cancer and nausea

The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.
  • Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs.
  • The Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019

Retrieved on: 
Friday, December 13, 2019
Medicine, Clinical medicine, Antineoplastic drugs, RTT, Antiemetics, Chemotherapy-induced nausea and vomiting, Cancer treatments, Chemotherapy, Breast cancer, Cancer, Oncology, Cancer and nausea

Lugano, Switzerland, December 13, 2019 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving chemotherapy-induced nausea and vomiting (CINV) amongst breast cancer patients receiving various treatments for CINV prophylaxis including NEPA, at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • Lugano, Switzerland, December 13, 2019 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving chemotherapy-induced nausea and vomiting (CINV) amongst breast cancer patients receiving various treatments for CINV prophylaxis including NEPA, at the San Antonio Breast Cancer Symposium (SABCS).
  • According to Dr. Schwartzberg: The acute care associated with CINV among patients receiving AC in the standard delivery of care represents a shortcoming both in clinical and economic outcomes.
  • We are encouraged by the results of this study to help address the unmet needs of CINV in patients taking AC chemotherapy.
  • In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need.

Global Cancer Supportive Care Drugs Markets, 2019-2026: Focus on Prevention and Management of Symptoms and Side-effects

Retrieved on: 
Thursday, November 14, 2019
Medicine, Clinical medicine, Pain, Medical specialties, Oncology, Opioids, Antiemetic, Analgesic, Chemotherapy-induced nausea and vomiting, Cancer and nausea

Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.

Key Points: 
  • Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.
  • Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis.
  • The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market.
  • High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.

Chemotherapy Induced Nausea & Vomiting - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2019
Health, Pharmaceutical, Medicine, Clinical medicine, Oncology, Medical specialties, Antineoplastic drugs, Antiemetics, Chemotherapy-induced nausea and vomiting, Chemotherapy, Vomiting, Cancer and nausea

The "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Nausea and Vomiting development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for Chemotherapy Induced Nausea and Vomiting
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chemotherapy Induced Nausea and Vomiting
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Global Antiemetics Technologies and Markets, 2023 - Vestibular Disorders, The Emergence of Advanced Therapies & Patent Expiry

Retrieved on: 
Monday, July 23, 2018
Medicine, Clinical medicine, Antiemetics, Oncology, 5-HT3 antagonists, Antineoplastic drugs, Vomiting, Chemotherapy-induced nausea and vomiting, Nausea, Chemotherapy, Serotonin, Cancer and nausea

Emesis is a devastating adverse effect of surgery, poisoning, chemotherapy, vestibular imbalance, medication, radiotherapy and during pregnancy.

Key Points: 
  • Emesis is a devastating adverse effect of surgery, poisoning, chemotherapy, vestibular imbalance, medication, radiotherapy and during pregnancy.
  • Antiemetics are used to suppress nausea and vomiting associated with CINV, PINV, NVP, RINV, motion sickness and vestibular sickness.
  • The 5-HT3 receptor antagonist market accounts for the largest market share of the global antiemetic market.
  • The Middle East and Africa antiemetic market are expected to grow at the highest rate during the forecast period.